Show simple item record

dc.contributor.authorGarcía Pavía, Pablo 
dc.date.accessioned2022-01-12T11:05:16Z
dc.date.available2022-01-12T11:05:16Z
dc.date.issued2021
dc.identifier.issn1388-9842spa
dc.identifier.urihttp://hdl.handle.net/10641/2639
dc.description.abstractAIMS: Dilated cardiomyopathy (DCM) associated with dystrophin gene (DMD) mutations in individuals with mild or absent skeletal myopathy are often indistinguishable from other DCM forms. We sought to describe the phenotype and prognosis of DMD associated DCM in DMD mutation carriers without severe skeletal myopathy. METHODS AND RESULTS: At 26 European centers, we retrospectively collected clinical characteristics and outcomes of 223 DMD mutation carriers (83% males, 33±15 years). 112 individuals (52%) had DCM at first evaluation (n=85; LVEF=34±11.2%) or developed DCM (n=27; LVEF 41.3±7.5%) after a median follow-up of 96 months (IQR: 5-311 months). DCM penetrance was 45% in carriers older than 40 years. DCM appeared earlier in males and was independent of the type of mutation, presence of skeletal myopathy, or elevated serum creatine kinase levels. Major adverse cardiac events (MACE) occurred in 22% individuals with DCM, 18% developed end-stage heart failure and 9% SCD or equivalent. Skeletal myopathy was not associated with survival free of MACE in patients with DCM. Decreased left ventricle ejection fraction and increased left ventricular end-diastolic diameter at baseline were associated with MACE. Individuals without DCM had favorable prognosis without MACE or death during follow-up. CONCLUSIONS: DMD-associated DCM without severe skeletal myopathy is characterized by incomplete penetrance but high risk of MACE, including progression to end-stage heart failure and ventricular arrhythmias. DCM onset is the major determinant of prognosis with similar survival regardless of the presence of skeletal myopathy.spa
dc.language.isoengspa
dc.publisherEuropean Journal of Heart Failurespa
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/es/*
dc.subjectDystrophinspa
dc.subjectDilated cardiomyopathyspa
dc.subjectHeart failurespa
dc.subjectMyopathyspa
dc.titlePrevalence and clinical outcomes of dystrophin-associated dilated cardiomyopathy without severe skeletal myopathy.spa
dc.typejournal articlespa
dc.type.hasVersionSMURspa
dc.rights.accessRightsopen accessspa
dc.description.extent797 KBspa
dc.identifier.doi10.1002/ejhf.2250spa
dc.relation.publisherversionhttps://onlinelibrary.wiley.com/doi/10.1002/ejhf.2250spa


Files in this item

FilesSizeFormatView
1.- Prevalence and Clinical ...796.1KbPDFView/Open

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España